Touro University California

Studies in animals have documented that, compared with glucose, dietary fructose induces dyslipidemia and insulin resistance. To assess the relative effects of these dietary sugars during sustained consumption in humans, overweight and obese subjects consumed glucose- or fructose-sweetened beverages providing 25% of energy requirements for 10 weeks. Although both groups exhibited similar weight gain during the intervention, visceral adipose volume was significantly increased only in subjects consuming fructose. Fasting plasma triglyceride concentrations increased by approximately 10% during 10 weeks of glucose consumption but not after fructose consumption. In contrast, hepatic de novo lipogenesis (DNL) and the 23-hour postprandial triglyceride AUC were increased specifically during fructose consumption. Similarly, markers of altered lipid metabolism and lipoprotein remodeling, including fasting apoB, LDL, small dense LDL, oxidized LDL, and postprandial concentrations of remnant-like particle-triglyceride and -cholesterol significantly increased during fructose but not glucose consumption. In addition, fasting plasma glucose and insulin levels increased and insulin sensitivity decreased in subjects consuming fructose but not in those consuming glucose. These data suggest that dietary fructose specifically increases DNL, promotes dyslipidemia, decreases insulin sensitivity, and increases visceral adiposity in overweight/obese adults.

BACKGROUND: Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether an alternative approach to inflammation inhibition with low-dose methotrexate might provide similar benefit. METHODS: We conducted a randomized, double-blind trial of low-dose methotrexate (at a target dose of 15 to 20 mg weekly) or matching placebo in 4786 patients with previous myocardial infarction or multivessel coronary disease who additionally had either type 2 diabetes or the metabolic syndrome. All participants received 1 mg of folate daily. The primary end point at the onset of the trial was a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Near the conclusion of the trial, but before unblinding, hospitalization for unstable angina that led to urgent revascularization was added to the primary end point. RESULTS: The trial was stopped after a median follow-up of 2.3 years. Methotrexate did not result in lower interleukin-1β, interleukin-6, or C-reactive protein levels than placebo. The final primary end point occurred in 201 patients in the methotrexate group and in 207 in the placebo group (incidence rate, 4.13 vs. 4.31 per 100 person-years; hazard ratio, 0.96; 95% confidence interval [CI], 0.79 to 1.16). The original primary end point occurred in 170 patients in the methotrexate group and in 167 in the placebo group (incidence rate, 3.46 vs. 3.43 per 100 person-years; hazard ratio, 1.01; 95% CI, 0.82 to 1.25). Methotrexate was associated with elevations in liver-enzyme levels, reductions in leukocyte counts and hematocrit levels, and a higher incidence of non-basal-cell skin cancers than placebo. CONCLUSIONS: Among patients with stable atherosclerosis, low-dose methotrexate did not reduce levels of interleukin-1β, interleukin-6, or C-reactive protein and did not result in fewer cardiovascular events than placebo. (Funded by the National Heart, Lung, and Blood Institute; CIRT ClinicalTrials.gov number, NCT01594333.).

Anticholinergic Drug Scale (ADS) scores were previously associated with serum anticholinergic activity (SAA) in a pilot study. To replicate these results, the association between ADS scores and SAA was determined using simple linear regression in subjects from a study of delirium in 201 long-term care facility residents who were not included in the pilot study. Simple and multiple linear regression models were then used to determine whether the ADS could be modified to more effectively predict SAA in all 297 subjects. In the replication analysis, ADS scores were significantly associated with SAA (R2 = .0947, P < .0001). In the modification analysis, each model significantly predicted SAA, including ADS scores (R2 = .0741, P < .0001). The modifications examined did not appear useful in optimizing the ADS. This study replicated findings on the association of the ADS with SAA. Future work will determine whether the ADS is clinically useful for preventing anticholinergic adverse effects.

The endoplasmic reticulum (ER) is the site of assembly of polypeptide chains destined for secretion or routing into various subcellular compartments. It also regulates cellular responses to stress and intracellular Ca(2+) levels. A variety of toxic insults can result in ER stress that ultimately leads to apoptosis. Apoptosis is initiated by the activation of members of the caspase family and serves as a central mechanism in the cell death process. The present study was carried out to determine the role of caspases in triggering ER stress-induced cell death. Treatment of cells with ER stress inducers such as brefeldin-A or thapsigargin induces the expression of caspase-12 protein and also leads to translocation of cytosolic caspase-7 to the ER surface. Caspase-12, like most other members of the caspase family, requires cleavage of the prodomain to activate its proapoptotic form. Caspase-7 associates with caspase-12 and cleaves the prodomain to generate active caspase-12, resulting in increased cell death. We propose that any cellular insult that causes prolonged ER stress may induce apoptosis through caspase-7-mediated caspase-12 activation. The data underscore the involvement of ER and caspases associated with it in the ER stress-induced apoptotic process.

Alterations in Ca(2+) homeostasis and accumulation of unfolded proteins in the endoplasmic reticulum (ER) lead to an ER stress response. Prolonged ER stress may lead to cell death. Glucose-regulated protein (GRP) 78 (Bip) is an ER lumen protein whose expression is induced during ER stress. GRP78 is involved in polypeptide translocation across the ER membrane, and also acts as an apoptotic regulator by protecting the host cell against ER stress-induced cell death, although the mechanism by which GRP78 exerts its cytoprotective effect is not understood. The present study was carried out to determine whether one of the mechanisms of cell death inhibition by GRP78 involves inhibition of caspase activation. Our studies indicate that treatment of cells with ER stress inducers causes GRP78 to redistribute from the ER lumen with subpopulations existing in the cytosol and as an ER transmembrane protein. GRP78 inhibits cytochrome c-mediated caspase activation in a cell-free system, and expression of GRP78 blocks both caspase activation and caspase-mediated cell death. GRP78 forms a complex with caspase-7 and -12 and prevents release of caspase-12 from the ER. Addition of (d)ATP dissociates this complex and may facilitate movement of caspase-12 into the cytoplasm to set in motion the cytosolic component of the ER stress-induced apoptotic cascade. These results define a novel protective role for GRP78 in preventing ER stress-induced cell death.

Partitioning of ATP generation between glycolysis and oxidative phosphorylation is central to cellular bioenergetics but cumbersome to measure. We describe here how rates of ATP generation by each pathway can be calculated from simultaneous measurements of extracellular acidification and oxygen consumption. We update theoretical maximum ATP yields by mitochondria and cells catabolizing different substrates. Mitochondrial P/O ratios (mol of ATP generated per mol of [O] consumed) are 2.73 for oxidation of pyruvate plus malate and 1.64 for oxidation of succinate. Complete oxidation of glucose by cells yields up to 33.45 ATP/glucose with a maximum P/O of 2.79. We introduce novel indices to quantify bioenergetic phenotypes. The glycolytic index reports the proportion of ATP production from glycolysis and identifies cells as primarily glycolytic (glycolytic index > 50%) or primarily oxidative. The Warburg effect is a chronic increase in glycolytic index, quantified by the Warburg index. Additional indices quantify the acute flexibility of ATP supply. The Crabtree index and Pasteur index quantify the responses of oxidative and glycolytic ATP production to alterations in glycolysis and oxidative reactions, respectively; the supply flexibility index quantifies overall flexibility of ATP supply; and the bioenergetic capacity quantifies the maximum rate of total ATP production. We illustrate the determination of these indices using C2C12 myoblasts. Measurement of ATP use revealed no significant preference for glycolytic or oxidative ATP by specific ATP consumers. Overall, we demonstrate how extracellular fluxes quantitatively reflect intracellular ATP turnover and cellular bioenergetics. We provide a simple spreadsheet to calculate glycolytic and oxidative ATP production rates from raw extracellular acidification and respiration data.

Exposure to the herbicide paraquat (PQ) is associated with an increased risk of idiopathic Parkinson's disease (PD). Therapies based on PQ's presumed mechanisms of action have not, however, yielded effective disease therapies. Cellular senescence is an anticancer mechanism that arrests proliferation of replication-competent cells and results in a pro-inflammatory senescence-associated secretory phenotype (SASP) capable of damaging neighboring tissues. Here, we demonstrate that senescent cell markers are preferentially present within astrocytes in PD brain tissues. Additionally, PQ was found to induce astrocytic senescence and an SASP in vitro and in vivo, and senescent cell depletion in the latter protects against PQ-induced neuropathology. Our data suggest that exposure to certain environmental toxins promotes accumulation of senescent cells in the aging brain, which can contribute to dopaminergic neurodegeneration. Therapies that target senescent cells may constitute a strategy for treatment of sporadic PD, for which environmental exposure is a major risk factor.

Transdermal drug delivery offers a number of advantages including improved patient compliance, sustained release, avoidance of gastric irritation, as well as elimination of pre-systemic first-pass effect. However, only few medications can be delivered through the transdermal route in therapeutic amounts. Microneedles can be used to enhance transdermal drug delivery. In this review, different types of microneedles are described and their methods of fabrication highlighted. Microneedles can be fabricated in different forms: hollow, solid, and dissolving. There are also hydrogel-forming microneedles. A special attention is paid to hydrogel-forming microneedles. These are innovative microneedles which do not contain drugs but imbibe interstitial fluid to form continuous conduits between dermal microcirculation and an attached patch-type reservoir. Several microneedles approved by regulatory authorities for clinical use are also examined. The last part of this review discusses concerns and challenges regarding microneedle use.

Hispanics are the largest minority group in the USA. They contribute to the economy, cultural diversity, and health of the nation. Assessing their health status and health needs is key to inform health policy formulation and program implementation. To this end, we conducted a scoping review of the literature and national statistics on Hispanic health in the USA using a modified social-ecological framework that includes social determinants of health, health disparities, risk factors, and health services, as they shape the leading causes of morbidity and mortality. These social, environmental, and biological forces have modified the epidemiologic profile of Hispanics in the USA, with cancer being the leading cause of mortality, followed by cardiovascular diseases and unintentional injuries. Implementation of the Affordable Care Act has resulted in improved access to health services for Hispanics, but challenges remain due to limited cultural sensitivity, health literacy, and a shortage of Hispanic health care providers. Acculturation barriers and underinsured or uninsured status remain as major obstacles to health care access. Advantageous health outcomes from the "Hispanic Mortality Paradox" and the "Latina Birth Outcomes Paradox" persist, but health gains may be offset in the future by increasing rates of obesity and diabetes. Recommendations focus on the adoption of the Health in All Policies framework, expanding access to health care, developing cultural sensitivity in the health care workforce, and generating and disseminating research findings on Hispanic health.

Ferroptosis is a newly defined form of regulated cell death characterized by the iron-dependent accumulation of lipid hydroperoxides. Erastin, the ferroptosis activator, binds to voltage-dependent anion channels VDAC2 and VDCA3, but treatment with erastin can result in the degradation of the channels. Here, the authors show that Nedd4 is induced following erastin treatment, which leads to the ubiquitination and subsequent degradation of the channels. Depletion of Nedd4 limits the protein degradation of VDAC2/3, which increases the sensitivity of cancer cells to erastin. By understanding the molecular mechanism of erastin-induced cellular resistance, we can discover how cells adapt to new molecules to maintain homeostasis. Furthermore, erastin-induced resistance mediated by FOXM1-Nedd4-VDAC2/3 negative feedback loop provides an initial framework for creating avenues to overcome the drug resistance of ferroptosis activators.

AIMS: Carnitine and choline are major nutrient precursors for gut microbiota-dependent generation of the atherogenic metabolite, trimethylamine N-oxide (TMAO). We performed randomized-controlled dietary intervention studies to explore the impact of chronic dietary patterns on TMAO levels, metabolism and renal excretion. METHODS AND RESULTS: Volunteers (N = 113) were enrolled in a randomized 2-arm (high- or low-saturated fat) crossover design study. Within each arm, three 4-week isocaloric diets (with washout period between each) were evaluated (all meals prepared in metabolic kitchen with 25% calories from protein) to examine the effects of red meat, white meat, or non-meat protein on TMAO metabolism. Trimethylamine N-oxide and other trimethylamine (TMA) related metabolites were quantified at the end of each diet period. A random subset (N = 13) of subjects also participated in heavy isotope tracer studies. Chronic red meat, but not white meat or non-meat ingestion, increased plasma and urine TMAO (each >two-fold; P < 0.0001). Red meat ingestion also significantly reduced fractional renal excretion of TMAO (P < 0.05), but conversely, increased fractional renal excretion of carnitine, and two alternative gut microbiota-generated metabolites of carnitine, γ-butyrobetaine, and crotonobetaine (P < 0.05). Oral isotope challenge revealed red meat or white meat (vs. non-meat) increased TMA and TMAO production from carnitine (P < 0.05 each) but not choline. Dietary-saturated fat failed to impact TMAO or its metabolites. CONCLUSION: Chronic dietary red meat increases systemic TMAO levels through: (i) enhanced dietary precursors; (ii) increased microbial TMA/TMAO production from carnitine, but not choline; and (iii) reduced renal TMAO excretion. Discontinuation of dietary red meat reduces plasma TMAO within 4 weeks.

CONTEXT: The definition of what constitutes a normal TSH during pregnancy is in flux. Recent studies suggested that the first trimester upper limit of normal for TSH should be 2.5 mIU/liter. OBJECTIVE: The objective of the study was to evaluate the pregnancy loss and preterm delivery rate in first-trimester thyroid peroxidase antibody-negative women with TSH values between 2.5 and 5.0 mIU/liter. DESIGN: The present study is a component of a recently published large-scale prospective trial that evaluated the impact of levothyroxine treatment on maternal and neonatal complications in thyroid peroxidase-positive women with TSH levels above 2.5 mIU/liter. The present study evaluated 4123 thyroid peroxidase antibody-negative women with TSH levels at or below 5.0 mIU/liter. Women were divided into two groups based on their initial TSH: group A, TSH level below 2.5 mIU/liter, excluding hyperthyroid women defined as an undetectable TSH with an elevated free T(4), and group B, TSH level between 2.5 and 5.0 mIU/liter. SETTING: The study was conducted at two ambulatory clinics of community hospitals in southern Italy. PATIENTS: A total of 4123 women were evaluated. INTERVENTION: There was no intervention. MAIN OUTCOME MEASURES: The incidence of pregnancy loss and preterm delivery in group A as compared with group B was measured. RESULTS: The rate of pregnancy loss was significantly higher in group B as compared with group A (6.1 vs. 3.6% respectively, P = 0.006). There was no difference in the rate of preterm delivery between the two groups. CONCLUSIONS: The increased incidence of pregnancy loss in pregnant women with TSH levels between 2.5 and 5.0 mIU/liter provides strong physiological evidence to support redefining the TSH upper limit of normal in the first trimester to 2.5 mIU/liter.

High-fructose diet stimulates hepatic de novo lipogenesis (DNL) and causes hypertriglyceridemia and insulin resistance in rodents. Fructose-induced insulin resistance may be secondary to alterations of lipid metabolism. In contrast, fish oil supplementation decreases triglycerides and may improve insulin resistance. Therefore, we studied the effect of high-fructose diet and fish oil on DNL and VLDL triglycerides and their impact on insulin resistance. Seven normal men were studied on four occasions: after fish oil (7.2 g/day) for 28 days; a 6-day high-fructose diet (corresponding to an extra 25% of total calories); fish oil plus high-fructose diet; and control conditions. Following each condition, fasting fractional DNL and endogenous glucose production (EGP) were evaluated using [1-13C]sodium acetate and 6,6-2H2 glucose and a two-step hyperinsulinemic-euglycemic clamp was performed to assess insulin sensitivity. High-fructose diet significantly increased fasting glycemia (7 +/- 2%), triglycerides (79 +/- 22%), fractional DNL (sixfold), and EGP (14 +/- 3%, all P < 0.05). It also impaired insulin-induced suppression of adipose tissue lipolysis and EGP (P < 0.05) but had no effect on whole- body insulin-mediated glucose disposal. Fish oil significantly decreased triglycerides (37%, P < 0.05) after high-fructose diet compared with high-fructose diet without fish oil and tended to reduce DNL but had no other significant effect. In conclusion, high-fructose diet induced dyslipidemia and hepatic and adipose tissue insulin resistance. Fish oil reversed dyslipidemia but not insulin resistance.

Using a modified social ecological model, we conducted a review of the literature and nationwide statistics on African American health. We discuss the main social determinants of health and main health disparities, risk factors, the leading causes of morbidity and mortality, and access to health services for blacks in the USA. The mechanisms through which social determinants, including racism, exert their deleterious effects on black health are discussed at the macro and individual levels. Incarceration and mental health care issues are highlighted as priorities to be addressed. African Americans remain the least healthy ethnic group in the USA, a somber legacy of years of racial and social injustice and a formidable challenge to equitable health care for all. Systemic causes of suboptimal black health require equally systemic solutions; positive trends in black health indicators seem to be driven by social development programs, economic investment in education, participation of African Americans in policy, and decision-making and expansion of access to health care.

ABSTRACT Diet can influence the composition of the human microbiome, and yet relatively few dietary ingredients have been systematically investigated with respect to their impact on the functional potential of the microbiome. Dietary resistant starch (RS) has been shown to have health benefits, but we lack a mechanistic understanding of the metabolic processes that occur in the gut during digestion of RS. Here, we collected samples during a dietary crossover study with diets containing large or small amounts of RS. We determined the impact of RS on the gut microbiome and metabolic pathways in the gut, using a combination of “omics” approaches, including 16S rRNA gene sequencing, metaproteomics, and metabolomics. This multiomics approach captured changes in the abundance of specific bacterial species, proteins, and metabolites after a diet high in resistant starch (HRS), providing key insights into the influence of dietary interventions on the gut microbiome. The combined data showed that a high-RS diet caused an increase in the ratio of Firmicutes to Bacteroidetes , including increases in relative abundances of some specific members of the Firmicutes and concurrent increases in enzymatic pathways and metabolites involved in lipid metabolism in the gut. IMPORTANCE This work was undertaken to obtain a mechanistic understanding of the complex interplay between diet and the microorganisms residing in the intestine. Although it is known that gut microbes play a key role in digestion of the food that we consume, the specific contributions of different microorganisms are not well understood. In addition, the metabolic pathways and resultant products of metabolism during digestion are highly complex. To address these knowledge gaps, we used a combination of molecular approaches to determine the identities of the microorganisms in the gut during digestion of dietary starch as well as the metabolic pathways that they carry out. Together, these data provide a more complete picture of the function of the gut microbiome in digestion, including links between an RS diet and lipid metabolism and novel linkages between specific gut microbes and their metabolites and proteins produced in the gut.

BACKGROUND: The aetiology and exact incidence of infantile haemangiomas (IHs) are unknown. Prior studies have noted immunohistochemical and biological characteristics shared by IHs and placental tissue. OBJECTIVES: We investigated the possible association between placental anomalies and the development of IHs, as well as the demographic characteristics and other risk factors for IHs. PATIENTS AND METHODS: Pregnant women (n = 578) were prospectively enrolled and their offspring followed for 9 months. Placental evaluations were performed and demographic data collected on all mother-infant pairs. RESULTS: We evaluated 594 infants: 34 haemangiomas [either IH or congenital (CH)] were identified in 29 infants, yielding an incidence of 4·5% for IH (27 infants) and 0·3% for CH (two infants). Placental anomalies were noted in almost 35% of haemangioma-related pregnancies, approximately twice the incidence noted in pregnancies with unaffected infants (P = 0·025). Other risk factors for IH included prematurity (P = 0·016) and low birth weight (P = 0·028). All IHs were present by 3 months of age, and cessation of growth had occurred in all by 9 months of age. Most occurred on the trunk. Of note, 20% of identified IHs were abortive or telangiectatic in nature, small focal lesions that did not proliferate beyond 3 months of age. Only one IH required intervention. CONCLUSIONS: This is the first prospective American study to document the incidence of IHs in infants followed from birth to early infancy. The association with placental anomalies was statistically significant. The overall incidence mirrors prior estimates, but the need for treatment was lower than previously reported.

The critical role of primary care clinicians (PCCs) in Alzheimer's disease (AD) prevention, diagnosis and management must evolve as new treatment paradigms and disease-modifying therapies (DMTs) emerge. Our understanding of AD has grown substantially: no longer conceptualized as a late-in-life syndrome of cognitive and functional impairments, we now recognize that AD pathology builds silently for decades before cognitive impairment is detectable. Clinically, AD first manifests subtly as mild cognitive impairment (MCI) due to AD before progressing to dementia. Emerging optimism for improved outcomes in AD stems from a focus on preventive interventions in midlife and timely, biomarker-confirmed diagnosis at early signs of cognitive deficits (i.e. MCI due to AD and mild AD dementia). A timely AD diagnosis is particularly important for optimizing patient care and enabling the appropriate use of anticipated DMTs. An accelerating challenge for PCCs and AD specialists will be to respond to innovations in diagnostics and therapy for AD in a system that is not currently well positioned to do so. To overcome these challenges, PCCs and AD specialists must collaborate closely to navigate and optimize dynamically evolving AD care in the face of new opportunities. In the spirit of this collaboration, we summarize here some prominent and influential models that inform our current understanding of AD. We also advocate for timely and accurate (i.e. biomarker-defined) diagnosis of early AD. In doing so, we consider evolving issues related to prevention, detecting emerging cognitive impairment and the role of biomarkers in the clinic.

INTRODUCTION AND AIMS: As the popularity of electronic cigarettes (e-cigarettes) increases, it is becoming important to find out more about the characteristics of e-cigarette users, why and how they use the product and whether e-cigarettes are used exclusively or in combination with conventional cigarettes. The objective of this study was to investigate patterns and effects of e-cigarette use and user beliefs about e-cigarette safety and benefits. DESIGN AND METHODS: E-cigarette users in Poland were recruited online and asked to participate in a web-based survey. The participants provided information on their smoking history, patterns of e-cigarette use, beliefs and attitudes regarding the product and information on concurrent use of conventional cigarettes. RESULTS: The survey was completed by 179 e-cigarette users. Almost all participants used e-cigarettes daily. E-cigarettes were primarily used to quit smoking or to reduce the harm associated with smoking (both 41%), and were successful in helping the surveyed users to achieve these goals with 66% not smoking conventional cigarettes at all and 25% smoking under five cigarettes a day. Most participants (82%) did not think that e-cigarettes were completely safe, but thought that they were less dangerous than conventional cigarettes. Sixty percent believed that e-cigarettes were addictive, but less so than conventional cigarettes. DISCUSSION AND CONCLUSIONS: The participants primarily used e-cigarettes as a stop-smoking aid or as an alternative to conventional cigarettes, and the majority reported that they successfully stopped smoking. More data on e-cigarette safety and its efficacy in harm-reduction and smoking cessation are needed.

Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) tract expansion near the N terminus of huntingtin (Htt). Proteolytic processing of mutant Htt and abnormal calcium signaling may play a critical role in disease progression and pathogenesis. Recent work indicates that calpains may participate in the increased and/or altered patterns of Htt proteolysis leading to the selective toxicity observed in HD striatum. Here, we identify two calpain cleavage sites in Htt and show that mutation of these sites renders the polyQ expanded Htt less susceptible to proteolysis and aggregation, resulting in decreased toxicity in an in vitro cell culture model. In addition, we found that calpain- and caspase-derived Htt fragments preferentially accumulate in the nucleus without the requirement of further cleavage into smaller fragments. Calpain family members, calpain-1, -5, -7, and -10, have increased levels or are activated in HD tissue culture and transgenic mouse models, suggesting they may play a key role in Htt proteolysis and disease pathology. Interestingly, calpain-1, -5, -7, and -10 localize to the cytoplasm and the nucleus, whereas the activated forms of calpain-7 and -10 are found only in the nucleus. These results support the role of calpain-derived Htt fragmentation in HD and suggest that aberrant activation of calpains may play a role in HD pathogenesis. Huntington's disease (HD) is a neurodegenerative disorder caused by a polyglutamine (polyQ) tract expansion near the N terminus of huntingtin (Htt). Proteolytic processing of mutant Htt and abnormal calcium signaling may play a critical role in disease progression and pathogenesis. Recent work indicates that calpains may participate in the increased and/or altered patterns of Htt proteolysis leading to the selective toxicity observed in HD striatum. Here, we identify two calpain cleavage sites in Htt and show that mutation of these sites renders the polyQ expanded Htt less susceptible to proteolysis and aggregation, resulting in decreased toxicity in an in vitro cell culture model. In addition, we found that calpain- and caspase-derived Htt fragments preferentially accumulate in the nucleus without the requirement of further cleavage into smaller fragments. Calpain family members, calpain-1, -5, -7, and -10, have increased levels or are activated in HD tissue culture and transgenic mouse models, suggesting they may play a key role in Htt proteolysis and disease pathology. Interestingly, calpain-1, -5, -7, and -10 localize to the cytoplasm and the nucleus, whereas the activated forms of calpain-7 and -10 are found only in the nucleus. These results support the role of calpain-derived Htt fragmentation in HD and suggest that aberrant activation of calpains may play a role in HD pathogenesis. Huntington's disease (HD) 1The abbreviations used are: HD, Huntington's disease; polyQ, polyglutamine; PARP, poly(ADP-ribose) polymerase; Pipes, 1,4-piperazinediethanesulfonic acid; Chaps, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; Bis-Tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol; NES, nuclear export signal; DEVD, Asp-Glu-Val-Asp. is an autosomal-dominant neurodegenerative disease caused by a CAG expansion in the huntingtin gene (htt) (1Huntington's Disease Collaborative Research GroupCell. 1993; 72: 971-983Abstract Full Text PDF PubMed Scopus (7080) Google Scholar), and is characterized by involuntary movements, personality changes, dementia, and early death (2Huntington G. J. Neuropsychiatry Clin. Neurosci. 2003; 15: 109-112Crossref PubMed Scopus (54) Google Scholar). Huntingtin protein (Htt) is expressed throughout the central nervous system as well as non-neuronal cells, yet causes selective neuronal death in the striatum and cortex (3DiFiglia M. Sapp E. Chase K. Schwarz C. Meloni A. Young C. Martin E. Vonsattel J.P. Carraway R. Reeves S.A. Boyce F.M. Aronin N. Neuron. 1995; 14: 1075-1081Abstract Full Text PDF PubMed Scopus (620) Google Scholar, 4Graveland G.A. Williams R.S. DiFiglia M. Science. 1985; 227: 770-773Crossref PubMed Scopus (497) Google Scholar, 5Sapp E. Ge P. Aizawa H. Bird E. Penney J. Young A.B. Vonsattel J.P. DiFiglia M. Neuroscience. 1995; 64: 397-404Crossref PubMed Scopus (141) Google Scholar, 6Hedreen J.C. Peyser C.E. Folstein S.E. Ross C.A. Neurosci. Lett. 1991; 133: 257-261Crossref PubMed Scopus (257) Google Scholar). The selective neurodegeneration found in HD may be linked to the expression of particular receptors and proteases in the affected striatal and cortical cells, but the molecular details of these events are not well characterized. One hypothesis that has received a great deal of attention is that production of N-terminal Htt fragments plays a key role in disease pathogenesis (7Mangiarini L. Sathasivam K. Seller M. Cozens B. Harper A. Hetherington C. Lawton M. Trottier Y. Lehrach H. Davies S.W. Bates G.P. Cell. 1996; 87: 493-506Abstract Full Text Full Text PDF PubMed Scopus (2593) Google Scholar, 8DiFiglia M. Sapp E. Chase K.O. Davies S.W. Bates G.P. Vonsattel J.P. Aronin N. Science. 1997; 277: 1990-1993Crossref PubMed Scopus (2322) Google Scholar, 9Goldberg Y.P. Nicholson D.W. Rasper D.M. Kalchman M.A. Koide H.B. Graham R.K. Bromm M. Kazemi-Esfarjani P. Thornberry N.A. Vaillancourt J.P. Hayden M.R. Nat. Genet. 1996; 13: 442-449Crossref PubMed Scopus (502) Google Scholar, 10Martindale D. Hackam A. Wieczorek A. Ellerby L. Wellington C. McCutcheon K. Singaraja R. Kazemi-Esfarjani P. Devon R. Kim S.U. Bredesen D.E. Tufaro F. Hayden M.R. Nat. Genet. 1998; 18: 150-154Crossref PubMed Scopus (422) Google Scholar). Our recent studies have shown that calpain cleaves Htt sites to N-terminal fragments J. Ellerby J. Neurosci. PubMed Google Scholar). In addition, we have that the of calpain is increased in the of HD suggesting that calpain-derived Htt fragments may to the of HD J. Ellerby J. Neurosci. PubMed Google Scholar). have as to Htt may early of the and these may be linked to and the activation of the the calpains N. A. Wellington Hayden M.R. Cell. Neurosci. PubMed Scopus Google Scholar, N. Wellington P. Hayden M.R. Neuron. Full Text Full Text PDF Scopus Google Scholar, H. A. Wellington Hayden M.R. Neuron. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). and receptors are in the striatum and play a role in the of in The of Htt receptors in the leading to N. A. Wellington Hayden M.R. Cell. Neurosci. PubMed Scopus Google Scholar, N. Wellington C. M. McCutcheon K. Hayden M.R. J. 72: PubMed Scopus Google Scholar, Y. A. J. Full Text Full Text PDF PubMed Scopus Google Scholar). The of Htt leading to receptors activation H. A. Wellington Hayden M.R. Neuron. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). the disease of Htt has in C.A. Hayden M.R. Nat. Neurosci. PubMed Scopus Google Scholar, 2003; PubMed Scopus Google Scholar). have shown that calpains and Htt Y.P. Nicholson D.W. Rasper D.M. Kalchman M.A. Koide H.B. Graham R.K. Bromm M. Kazemi-Esfarjani P. Thornberry N.A. Vaillancourt J.P. Hayden M.R. Nat. Genet. 1996; 13: 442-449Crossref PubMed Scopus (502) Google Scholar, 10Martindale D. Hackam A. Wieczorek A. Ellerby L. Wellington C. McCutcheon K. Singaraja R. Kazemi-Esfarjani P. Devon R. Kim S.U. Bredesen D.E. Tufaro F. Hayden M.R. Nat. Genet. 1998; 18: 150-154Crossref PubMed Scopus (422) Google Scholar, J. Ellerby J. Neurosci. PubMed Google Scholar, Ellerby Hackam M.A. Singaraja R. McCutcheon K. Bromm M. Rasper D. Thornberry N. L. A. Ross C.A. Nicholson D.W. Bredesen D.E. Hayden M.R. J. 1998; Full Text Full Text PDF PubMed Scopus (497) Google Scholar, Singaraja R. Wellington M. McCutcheon K. Kalchman M. Hayden M.R. J. 1998; PubMed Scopus Google Scholar, Singaraja R. Ellerby L. J. B. E. Hackam A. A. Thornberry N. Nicholson D.W. Bredesen D.E. Hayden M.R. J. Full Text Full Text PDF PubMed Scopus Google Scholar, Ellerby C.A. D. Graham R.K. J. Singaraja R. J. Bredesen D. Nicholson D.W. Hayden M.R. J. Neurosci. PubMed Google Scholar). is the processing of Htt in vitro and in Y.P. Nicholson D.W. Rasper D.M. Kalchman M.A. Koide H.B. Graham R.K. Bromm M. Kazemi-Esfarjani P. Thornberry N.A. Vaillancourt J.P. Hayden M.R. Nat. Genet. 1996; 13: 442-449Crossref PubMed Scopus (502) Google Scholar, 10Martindale D. Hackam A. Wieczorek A. Ellerby L. Wellington C. McCutcheon K. Singaraja R. Kazemi-Esfarjani P. Devon R. Kim S.U. Bredesen D.E. Tufaro F. Hayden M.R. Nat. Genet. 1998; 18: 150-154Crossref PubMed Scopus (422) Google Scholar, Ellerby Hackam M.A. Singaraja R. McCutcheon K. Bromm M. Rasper D. Thornberry N. L. A. Ross C.A. Nicholson D.W. Bredesen D.E. Hayden M.R. J. 1998; Full Text Full Text PDF PubMed Scopus (497) Google Scholar, Singaraja R. Wellington M. McCutcheon K. Kalchman M. Hayden M.R. J. 1998; PubMed Scopus Google Scholar, Singaraja R. Ellerby L. J. B. E. Hackam A. A. Thornberry N. Nicholson D.W. Bredesen D.E. Hayden M.R. J. Full Text Full Text PDF PubMed Scopus Google Scholar, Ellerby C.A. D. Graham R.K. J. Singaraja R. J. Bredesen D. Nicholson D.W. Hayden M.R. J. Neurosci. PubMed Google Scholar). is not Htt the in a neurodegenerative and the of of the family has in the cell death Y.P. Nicholson D.W. Rasper D.M. Kalchman M.A. Koide H.B. Graham R.K. Bromm M. Kazemi-Esfarjani P. Thornberry N.A. Vaillancourt J.P. Hayden M.R. Nat. Genet. 1996; 13: 442-449Crossref PubMed Scopus (502) Google Scholar, J. Cell. 1993; Full Text PDF PubMed Scopus Google Scholar). is the role of calpain family in cell death and and family calpain have A. A. Full Text Full Text PDF PubMed Scopus Google Scholar, Y. Full Text Full Text PDF PubMed Scopus Google Scholar, D.E. 1991; PubMed Scopus Google Scholar). of the family found in the have not characterized Y. Full Text Full Text PDF PubMed Scopus Google Scholar). The calpains and and have and are by in activation whereas levels N. M. A. N. J. Full Text PDF PubMed Google Scholar, Neurosci. Full Text Full Text PDF PubMed Scopus Google Scholar, H. K. J. 1997; PubMed Scopus (620) Google Scholar, H. K. J. PubMed Scopus Google Scholar). the of a protein to a whereas activation of the results in the protein N The is to calpains and cleavage events to the into the are activated by and that levels in the cell and activation of activation A. 1998; PubMed Scopus Google Scholar, N. Y. PubMed Scopus Google Scholar, 1998; PubMed Scopus Google Scholar, H. R. J. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar, C. N. M. J. Full Text Full Text PDF PubMed Scopus Google Scholar, Y. J. PubMed Scopus Google Scholar, M. H. J.C. J. Full Text Full Text PDF PubMed Scopus Google Scholar, K. P. J. Full Text Full Text PDF PubMed Scopus Google Scholar). -7, -10, and are expressed in the but or have not is expressed and may have a role in Y. Full Text Full Text PDF PubMed Scopus Google Scholar). has as a gene Y. N. M. M. Y. H. Schwarz L. Y. P. N. J. C. L. E. Nat. Genet. PubMed Scopus Google and is a of a gene M. Young 1998; PubMed Scopus Google Scholar). found to be to the nucleus, and nuclear H. C. Kim N.A. M. M. J. Full Text Full Text PDF PubMed Scopus Google Scholar). of to the cleavage events in HD, we the role calpain cleavage plays in Htt toxicity and of the calpain family are expressed or activated altered in HD cell culture and transgenic mouse found that calpains Htt and The sites of cleavage are an that cleavage sites in Htt toxicity and Htt observed the of Htt expressed in a cell culture altered The Htt fragments found to preferentially accumulate in the nuclear without the requirement of further we found calpain family calpain-1, -5, -7, and -10 levels are increased and/or activated in HD tissue culture and transgenic mouse and expression used in these studies the and and forms of the and N-terminal Htt and have Y.P. Nicholson D.W. Rasper D.M. Kalchman M.A. Koide H.B. Graham R.K. Bromm M. Kazemi-Esfarjani P. Thornberry N.A. Vaillancourt J.P. Hayden M.R. Nat. Genet. 1996; 13: 442-449Crossref PubMed Scopus (502) Google Scholar, 10Martindale D. Hackam A. Wieczorek A. Ellerby L. Wellington C. McCutcheon K. Singaraja R. Kazemi-Esfarjani P. Devon R. Kim S.U. Bredesen D.E. Tufaro F. Hayden M.R. Nat. Genet. 1998; 18: 150-154Crossref PubMed Scopus (422) Google Scholar, Singaraja R. Ellerby L. J. B. E. Hackam A. A. Thornberry N. Nicholson D.W. Bredesen D.E. Hayden M.R. J. Full Text Full Text PDF PubMed Scopus Google Scholar). used to identify and calpain cleavage of and as well as in the and and forms of the and N-terminal Htt fragments and to and In addition, or in the as calpain cleavage sites by the of of of and and of and and into and the by of calpain cleavage sites calpain cleavage of in vitro as as well as of Htt cleavage in J. Ellerby J. Neurosci. PubMed Google Scholar). of a to the and The a of of and of and The a and into a a used of Htt or or and or cell or mouse tissue in Wellington Hackam Ross C.A. Hayden M.R. Bredesen D.E. J. Full Text Full Text PDF PubMed Scopus Google Scholar, Hackam Ellerby M.A. L. Wellington Hayden M.R. Bredesen D.E. J. 72: PubMed Scopus Google Scholar), or the nuclear and in the of of of mouse to and Htt Htt Htt N-terminal Htt Ellerby C.A. D. Graham R.K. J. Singaraja R. J. Bredesen D. Nicholson D.W. Hayden M.R. J. Neurosci. PubMed Google Scholar), Htt Htt Research Research calpain calpain calpain-7 R. J. Neurosci. 14: PubMed Google or and and used to of a and the in cell to cell to Pipes, Chaps, and and an of and an of a The of in the to protein levels to levels the in Htt or Research by or used as a nuclear Calpain a to the The in to a of in a J. 1993; PubMed Scopus Google the or or and or of of and of in a of of and tissue HD in a and by the into of Htt and the and and to of of Calpain in have shown that calpains Htt to N-terminal cleavage J. Ellerby J. Neurosci. PubMed Google Scholar). In we found that of in vitro or and N-terminal two of and are in to the of Htt in cell culture and in vitro the Htt calpain cleavage and the sites and and The of cleavage in Htt and calpain cleavage toxicity of the of Htt not in work J. Ellerby J. Neurosci. PubMed Google Scholar). we the of calpain cleavage in Htt and the of these in a cell culture model. of calpain used to identify calpain cleavage sites in the of calpain cleavage sites have in calpains the of protein D.E. 1991; PubMed Scopus Google Scholar). the only we a of an calpain cleavage in protein D.E. 1991; PubMed Scopus Google Scholar), cleavage of Htt by of expressed in Htt cleavage and found that expressed in cells, to calpain cleavage and production of the calpain-derived Htt and in vitro of calpain the production of the we the calpain cleavage in Htt that the a of is an calpain cleavage in J. J. PubMed Scopus Google Scholar). found that expressed in cells, to calpain cleavage and production of the calpain-derived Htt and we the Htt calpain sites of or in the and calpain fragments and The Htt cleavage and and are caspase-derived and of the of we in Htt calpain cleavage only the calpain cleavage sites and found these calpain proteolysis of of a calpain cleavage not production of the calpain-derived Htt in expressed in of a calpain in not the production of the calpain-derived Htt of calpain cleavage sites to the or not calpain cleavage of Htt and further the of these and the to in calpain proteolysis and toxicity of we of these calpain cleavage sites cleavage of Htt these sites are in to of these and not and production of caspase-derived Htt fragments these are expressed in culture they susceptible to The calpain cleavage of Htt by a to Htt calpain cleavage is levels of the of the N-terminal Htt Htt Htt protein to used as a and the molecular as the cleavage not to identify the calpain cleavage the N-terminal Htt to and a to two of the calpain cleavage sites and of these production of the calpain-derived Htt not the N-terminal cleavage a calpain cleavage of Htt in cell culture not of not Htt in an in work we the proteolysis and toxicity of Htt in tissue culture that activated cell death Singaraja R. Ellerby L. J. B. E. Hackam A. A. Thornberry N. Nicholson D.W. Bredesen D.E. Hayden M.R. J. Full Text Full Text PDF PubMed Scopus Google Scholar). is not of cell death activation is in recent that altered plays an role in HD pathogenesis and progression N. C.A. F. Singaraja R. N. McCutcheon K. J. L. E. J.C. Hayden M.R. Neuron. Full Text Full Text PDF PubMed Scopus Google Scholar). we a cell culture to the cleavage of Htt by and calpains that levels J. Ellerby J. Neurosci. PubMed Google Scholar). or Htt a that levels of the and and of the of in or Htt or and N-terminal Htt of Htt in and Htt the in of calpain family in a cell culture model. levels of calpain family in calpain protein levels and activation in The forms are by and forms by and of by and or increased levels of the and of calpain by and in increased levels of Htt cleavage to are increased cleavage of Htt but less of the cleavage Htt and that the of the Htt cleavage to be The of cleavage to is to in the the of Htt we cell culture that and the calpain cleavage sites in we to calpain cleavage of Htt and we expressed the in and of the of in the tissue culture as by to a in to The of protein the The protein suggesting to The in not to altered levels of Htt expression as by not Htt Htt and in an in cleavage have Htt in that may toxicity and These cleavage of Htt by Y.P. Nicholson D.W. Rasper D.M. Kalchman M.A. Koide H.B. Graham R.K. Bromm M. Kazemi-Esfarjani P. Thornberry N.A. Vaillancourt J.P. Hayden M.R. Nat. Genet. 1996; 13: 442-449Crossref PubMed Scopus (502) Google Scholar, Singaraja R. Ellerby L. J. B. E. Hackam A. A. Thornberry N. Nicholson D.W. Bredesen D.E. Hayden M.R. J. Full Text Full Text PDF PubMed Scopus Google Scholar), calpains J. Ellerby J. Neurosci. PubMed Google Scholar, Y. Sapp E. Y. B. Aronin N. DiFiglia M. A. PubMed Scopus Google Scholar), and an A. L. C. D. Trottier Y. Cell. Full Text Full Text PDF PubMed Scopus Google Scholar). these or is not we Htt we cleavage these Htt calpain sites and the production of smaller N-terminal fragments. a in proteolysis to of not only production of the calpain-derived cleavage but to a in further proteolysis of Htt by a in the of molecular N-terminal Htt cleavage observed the of may the N-terminal Htt A. L. C. D. Trottier Y. Cell. Full Text Full Text PDF PubMed Scopus Google Scholar). The protein a in Htt to and a in the of Htt in the by as well as a in the and of observed in to In whereas these the these have and HD the that the Htt is less be that in cleavage and observed Htt a N-terminal Htt and Htt Calpain and of Htt to the of fragments in the nucleus has in HD, as well as polyQ D. Hackam A. Wieczorek A. Ellerby L. Wellington C. McCutcheon K. Singaraja R. Kazemi-Esfarjani P. Devon R. Kim S.U. Bredesen D.E. Tufaro F. Hayden M.R. Nat. Genet. 1998; 18: 150-154Crossref PubMed Scopus (422) Google Scholar, Singaraja R. Wellington M. McCutcheon K. Kalchman M. Hayden M.R. J. 1998; PubMed Scopus Google Scholar, Genet. PubMed Scopus Google Scholar, H. H.B. Cell. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar, Singaraja R. L. Hayden M.R. Genet. PubMed Scopus Google Scholar, J. Ross C.A. Cell. Neurosci. 14: PubMed Scopus Google Scholar, G. K. M. N.A. H. Ross C.A. Neuron. Full Text Full Text PDF PubMed Scopus Google Scholar, Ellerby Wellington A. Hayden M.R. Ross C.A. J. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar). toxicity of N-terminal Htt fragments be by of a nuclear and decreased by of a nuclear export J. Ross C.A. Cell. Neurosci. 14: PubMed Scopus Google Scholar). Htt a NES, suggesting Htt may and the and nucleus J. J. M. R. Genet. 2003; PubMed Google Scholar). The of Htt is suggesting the of the in the of Htt Meloni Y. Kim E. Sapp E. Y. Aronin N. DiFiglia M. J. 277: Full Text Full Text PDF PubMed Scopus Google Scholar, C.A. M. H. Vonsattel J.P. Genet. PubMed Scopus Google Scholar). studies have Htt be to or less N-terminal fragments to preferentially accumulate in the nucleus, fragments may not to the nucleus further D. Hackam A. Wieczorek A. Ellerby L. Wellington C. McCutcheon K. Singaraja R. Kazemi-Esfarjani P. Devon R. Kim S.U. Bredesen D.E. Tufaro F. Hayden M.R. Nat. Genet. 1998; 18: 150-154Crossref PubMed Scopus (422) Google Scholar, Singaraja R. Wellington M. McCutcheon K. Kalchman M. Hayden M.R. J. 1998; PubMed Scopus Google Scholar, Singaraja R. L. Hayden M.R. Genet. PubMed Scopus Google Scholar). These studies Htt and not is of to fragments the cytoplasm to the nucleus. In addition, a of Htt in the nucleus, and is to cleavage in Htt cleavage the nucleus, of and in to production of calpain-derived Htt fragments. Htt the nucleus only in the nuclear Interestingly, of the observed in the nucleus as well as the is the of the Htt in these In addition, we found calpain and Htt cleavage accumulate in the nucleus and the calpain-derived Htt cleavage in the and nuclear the calpain-derived Htt cleavage to the nuclear have and characterized Htt that the cleavage of Htt and Ellerby C.A. D. Graham R.K. J. Singaraja R. J. Bredesen D. Nicholson D.W. Hayden M.R. J. Neurosci. PubMed Google Scholar). the the Htt cleavage in the nuclear and not the results observed the Htt cleavage by to the and the nuclear studies the the nuclear of the Htt cleavage of into Our studies not cleavage of Htt in the nucleus or Calpain to and in the proteolysis of and nuclear by family has of calpain cleavage events is of the calpain family calpain-1, and have well characterized. calpain family members, and are expressed in the tissue H. C. Kim N.A. M. M. J. Full Text Full Text PDF PubMed Scopus Google E. J. E. C. L. M. R. and L. M. and may play a role in HD pathogenesis. In addition, levels of -7, and -10 are altered in the HD mouse E. J. E. C. L. M. R. and L. M. further further calpain and Htt and in cleavage of calpain and to of the and forms of these proteases that and forms of as well as the calpain to the and -10 the in nuclear and and the in the nuclear and forms of found in the and nucleus in these studies as as well as is activated of J. J. PubMed Scopus Google Scholar). The of to the nucleus and whereas the to the The of forms of and to the found less activation of in the in these studies to the used to in studies Singaraja R. Ellerby L. J. B. E. Hackam A. A. Thornberry N. Nicholson D.W. Bredesen D.E. Hayden M.R. J. Full Text Full Text PDF PubMed Scopus Google Scholar). we and/or of calpains by in cell culture studies that -7, and -10 are increased to increased an in -7, and -10 protein levels activation of calpain family These results are increased calpain protein and activation of calpains altered we the and activation of calpain family in cell culture in by these proteases in an HD mouse model. in an HD Calpain the of calpain activation and proteolysis in HD in we an HD mouse mouse Htt polyQ A.B. Genet. PubMed Scopus Google Scholar). In studies we and to gene proteolysis and activation of The HD transgenic mouse has and HD A.B. Genet. PubMed Scopus Google Scholar). are found in and The are nuclear of Htt and protein in the striatum. found increased calpain and Htt fragmentation in the cortex and striatum of HD transgenic particular is the gene a to the calpain-derived cleavage of R. J. Neurosci. 14: PubMed Google and a in the the levels to or in the cleavage and a in found in the striatum of to as by calpain family altered in the cortex of the and of and -10 expression in the cortex a gene the the levels the or of these have A.B. Genet. PubMed Scopus Google Scholar). used to the role calpains play in the proteolysis of Htt in HD cell culture and transgenic mouse One HD is that production of fragments of the of Htt to HD and progression (7Mangiarini L. Sathasivam K. Seller M. Cozens B. Harper A. Hetherington C. Lawton M. Trottier Y. Lehrach H. Davies S.W. Bates G.P. Cell. 1996; 87: 493-506Abstract Full Text Full Text PDF PubMed Scopus (2593) Google Scholar, 8DiFiglia M. Sapp E. Chase K.O. Davies S.W. Bates G.P. Vonsattel J.P. Aronin N. Science. 1997; 277: 1990-1993Crossref PubMed Scopus (2322) Google Scholar, 9Goldberg Y.P. Nicholson D.W. Rasper D.M. Kalchman M.A. Koide H.B. Graham R.K. Bromm M. Kazemi-Esfarjani P. Thornberry N.A. Vaillancourt J.P. Hayden M.R. Nat. Genet. 1996; 13: 442-449Crossref PubMed Scopus (502) Google Scholar, 10Martindale D. Hackam A. Wieczorek A. Ellerby L. Wellington C. McCutcheon K. Singaraja R. Kazemi-Esfarjani P. Devon R. Kim S.U. Bredesen D.E. Tufaro F. Hayden M.R. Nat. Genet. 1998; 18: 150-154Crossref PubMed Scopus (422) Google Scholar). of the cleavage in Htt we used to identify two calpain sites in Htt and These calpain sites are and an that cleavage sites in Htt suggesting of Htt is susceptible to cleavage found expression of the Htt and Htt In we the forms of the Htt that activation but not Singaraja R. Ellerby L. J. B. E. Hackam A. A. Thornberry N. Nicholson D.W. Bredesen D.E. Hayden M.R. J. Full Text Full Text PDF PubMed Scopus Google Scholar). In we found that the of Htt has calpain cleavage of is an early in HD pathogenesis and activation of calpains may be in Htt proteolysis and a in vitro model. cleavage have Htt in that may toxicity and These cleavage of Htt by Y.P. Nicholson D.W. Rasper D.M. Kalchman M.A. Koide H.B. Graham R.K. Bromm M. Kazemi-Esfarjani P. Thornberry N.A. Vaillancourt J.P. Hayden M.R. Nat. Genet. 1996; 13: 442-449Crossref PubMed Scopus (502) Google Scholar, Singaraja R. Ellerby L. J. B. E. Hackam A. A. Thornberry N. Nicholson D.W. Bredesen D.E. Hayden M.R. J. Full Text Full Text PDF PubMed Scopus Google Scholar), calpains J. Ellerby J. Neurosci. PubMed Google Scholar, Y. Sapp E. Y. B. Aronin N. DiFiglia M. A. PubMed Scopus Google Scholar), and an A. L. C. D. Trottier Y. Cell. Full Text Full Text PDF PubMed Scopus Google Scholar). these are of or in a is not of the Htt that cleavage the calpain sites is the production smaller N-terminal fragments a cleavage model. found that calpains and Htt of Htt by and Htt by the of Htt calpain cleavage of Htt In addition, Htt cleavage Our studies not the of activation of the family in is not yet the of or proteases to HD we that a of calpain family may be increased and activated in HD tissue culture and transgenic mouse found that an of the increased and of -7, and -10 in cell culture model. tissue culture studies we found that the of calpain-1, -5, -7, and -10 increased in striatal or cortical tissue in an HD mouse suggesting these calpain family may be in the of One particular studies is that the Htt cleavage accumulate in the nucleus without the requirement of further cleavage into smaller fragments. work that of the Htt fragments is and of Htt in the nucleus D. Hackam A. Wieczorek A. Ellerby L. Wellington C. McCutcheon K. Singaraja R. Kazemi-Esfarjani P. Devon R. Kim S.U. Bredesen D.E. Tufaro F. Hayden M.R. Nat. Genet. 1998; 18: 150-154Crossref PubMed Scopus (422) Google Scholar, Singaraja R. Wellington M. McCutcheon K. Kalchman M. Hayden M.R. J. 1998; PubMed Scopus Google Scholar). studies not the of Htt we the and activation of calpain and in the cytoplasm and nucleus. found a of calpain are to the nucleus suggesting that Htt be in Our work that calpains play a role in Htt proteolysis and HD pathology. work be of these calpain family play a critical role in HD and is the activation and of of these calpain family and particular to HD or calpains are in HD the studies are in and work calpains are HD and the and HD are to the Disease support to and and to the Huntington's Disease of support of and to A. Ross

Problem: Rates of walking and bicycling to school have declined sharply in recent decades, and federal and state governments have committed funds to reverse these trends. To increase rates of walking and biking to school will require understanding why many parents choose to drive their children to school and how well existing programs, like Safe Routes to School, work. Purpose: We aimed to understand why many parents choose to drive their children even short distances to school, and what implications this has for programs to increase walking and biking to school. Methods: We used data from a telephone survey to explore why parents drive their children to school. Results and conclusions: We found that 75% of parents driving their children less than 2 miles to school said they did this for convenience and to save time. Nearly half of parents driving their children less than 2 miles did not allow their child to walk to school without adult supervision. Accompanying a child on a walk to school greatly increases the time the household devotes to such a trip. Few Safe Routes to School programs effectively address issues of parental convenience and time constraints. Takeaway for practice: Safe Routes to School programs should take parental convenience and time constraints into account by providing ways children can walk to school supervised by someone other than the parent, such as by using walking school buses. To be effective, such programs need institutional support. Schools should take a multimodal approach to pupil transportation. Research support: This research was funded by the Active Living Research program of the Robert Wood Johnson Foundation and the U.S. and California Departments of Transportation through the University of California Transportation Center.